Madrigal Pharmaceuticals
MDGL
379.10
-17.64
-4.45%
Madrigal Pharmaceuticals
US · MDGL
#1355 by market cap
Listed 2016
379.10
-17.64
-4.45%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 35 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.5 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 106.26% -1.49pp
- Institutions
- 544 +35
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund53.97%
Hedge Fund41.11%
Private Company5.74%
Individual/Insider5.20%
Public Company3.19%
Government Pension Fund0.98%
Sovereign Wealth Fund0.93%
Insurance Company0.19%
Top holders as of 2026-11-06
Baker Bros. Advisors LP
8.78% · 2.04M sh
RTW Investments, LP
8.58% · 1.99M sh
Janus Henderson Group plc
8.33% · 1.94M sh
Avoro Capital Advisors LLC
7.89% · 1.83M sh
Paulson & Co. Inc.
5.77% · 1.34M sh
BlackRock
5.33% · 1.24M sh
Vanguard Capital Management, LLC
3.64% · 846.64K sh
Wellington Management Group
3.55% · 825.71K sh
Vanguard Portfolio Management, LLC
3.28% · 761.02K sh
SQN, LLC
2.82% · 655.54K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 30 buys · 20 sells
| Name | Role | Stake |
|---|---|---|
| Rebecca Taub | Founder, Senior Scientific & Medical Advisor and Director | 1.90% |
| Frederick Craves | Former Lead Independent Director | 1.58% |
| Paul Friedman | Former Director | 0.74% |
| William Sibold | Chief Executive Officer | 0.66% |
| Brian Lynch | Former Senior Vice President | 0.11% |
| Richard Levy | Independent Director | 0.09% |
| David Soergel | Chief Medical Officer | 0.04% |
| Robert Waltermire | Chief Pharmaceutical Development Officer | 0.02% |
| Raymond Cheong | Independent Director | 0.02% |
| James Daly | Independent Director | 0.01% |
| Julian Baker | Independent Chairperson | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-05 | Baker Bros. Advisors LP | -- | Open Market Acquisition | +91,806 | $366.99–396.61 |
| 2026-11-05 | Shannon Kelley | Executive Vice President | Open Market Disposition | -1,077 | $400.00 |
| 2026-09-27 | Paul Friedman | Former Director | Intent to Sell (Form 144) | -50,000 | $516.56 |
| 2026-09-10 | William Sibold | Chief Executive Officer | Automatic Disposition | -5,221 | $533.09–546.38 |
| 2026-09-08 | William Sibold | Chief Executive Officer | Open Market Disposition | -6,362 | $527.88–542.55 |
| 2026-08-16 | Shannon Kelley | Executive Vice President | Open Market Disposition | -664 | $514.97 |
| 2026-08-14 | John Reed | Director | Other Acquisition | +647 | -- |
| 2026-08-14 | John Reed | Director | Other Derivative Acquisition | +1,078 | $507.56 |
| 2026-07-19 | William Sibold | Chief Executive Officer | Derivative Exercise and Sale | -2,500 | $542.75–555.05 |
| 2026-07-16 | William Sibold | Chief Executive Officer | Derivative Exercise and Retained | +47,500 | -- |
| 2026-06-16 | Julian Baker | Independent Chairperson | Other Acquisition | +454 | -- |
| 2026-06-16 | Julian Baker | Independent Chairperson | Other Derivative Acquisition | +766 | $499.86 |
| 2026-06-16 | Jacqualyn Fouse | Independent Director | Other Acquisition | +454 | -- |
| 2026-06-16 | Jacqualyn Fouse | Independent Director | Other Derivative Acquisition | +766 | $499.86 |
| 2026-06-16 | Richard Levy | Independent Director | Other Acquisition | +454 | -- |
| 2026-06-16 | Richard Levy | Independent Director | Other Derivative Acquisition | +766 | $499.86 |
| 2026-06-16 | Rebecca Taub | Founder, Senior Scientific & Medical Advisor and Director | Other Acquisition | +454 | -- |
| 2026-06-16 | Rebecca Taub | Founder, Senior Scientific & Medical Advisor and Director | Other Derivative Acquisition | +766 | $499.86 |
| 2026-06-16 | James Daly | Independent Director | Other Acquisition | +454 | -- |
| 2026-06-16 | James Daly | Independent Director | Other Derivative Acquisition | +766 | $499.86 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Madrigal Pharmaceuticals discussion 0 comments